2024 Medical IP Practice Training Programme (Session 2 · Shanghai)
About the Conference
About the Conference
On 30-31 May 2024, Session 2 of the Medical IP Practice Training Programme, jointly organised by the IP Practice Centre (BIPI) and Zhichan Huicui, was held at the Holiday Inn Shanghai Hongqiao West, with IP managers from pharmaceutical companies and legal practitioners in attendance.
Building on Session 1, this edition approached the subject from two directions — the macro institutional framework and the practical operation of specific rules. Experts, judges and lawyers with years of depth in pharmaceutical IP were invited to unpack the hot and difficult issues under the current regime and to offer workable approaches for biopharma companies.
Six instructors covered the influence of the US Hatch-Waxman Act on China's legislation, examination standards and judicial practice for supplementary experimental data, strategies and procedures for generic drug patent challenges, IP protection systems in biopharma companies, and a comparison of patent linkage rules across the Chinese mainland, Taiwan, China and the United States.
On Site
Moments
Why Attend
Highlights
- 01
Six instructors spanning institutional history, examination standards, generic challenges and patent linkage comparison
- 02
Supplementary experimental data examined from both the patent office and the judicial perspective
- 03
A three-way comparison of patent linkage rules across the Chinese mainland, Taiwan, China and the United States
- 04
Classroom teaching combined with interactive Q&A, well received by participants
Topics & Agenda
Key Topics
Institutional history and examination standards
04- The influence of the US Hatch-Waxman Act on China's pharmaceutical legislation
- Evolution and practice of examination standards for supplementary experimental data
- Judicial rules on supplementary experimental data from the courts' perspective
- The pros and cons of relaxed standards and where they are heading
Generic challenges and patent linkage
04- Strategies and procedures for generic drug patent challenges
- Identifying and assessing blocking patents, and designing around them
- Patent search, invalidation, priority verification and confidentiality review
- Patent linkage compared across the Chinese mainland, Taiwan, China and the United States
Corporate IP management
03- IP protection systems in biopharma companies
- Portfolio planning, risk control and patent term extension
- Making use of the early pharmaceutical patent dispute resolution mechanism
Overview of Speakers
Speakers
Yongshun Cheng
Renowned IP Expert
Qingkui Zhang
China National Intellectual Property Administration
Former Director, Chemistry Examination Dept. and Pharmaceuticals & Biotechnology Examination Dept.
Qinghui Liu
Beijing AnJie Broad Law Firm
Partner
Weibin Wang
Shanghai Bixing Law Firm
Managing Partner
Caihui Li
Juntuo Biopharma
Head of IP
Qingchen Hou
Qingchen Law Firm, Taiwan, China · Founder, Nanjing Huaxun IP Consulting
Founding Partner
Hosted By
Organisers
MIPT-2024-SH · see you at the next edition
For the full agenda or registration details, get in touch with the organising committee — we usually reply within one business day.
Full Report
Read the full post-event report
Originally published on our WeChat account, including the full session recap and photo gallery.